布鲁顿酪氨酸激酶：骨髓瘤中的癌基因靶点
Bruton's tyrosine kinase: oncotarget in myeloma.
作者信息
Tai Yu-Tzu, Anderson Kenneth C
出版信息
Oncotarget. 2012 Sep;3(9):913-4. doi: 10.18632/oncotarget.655.
Abstract
Our findings therefore provide a strong rationale for investigating Btk inhibitors in MM and WM to target both tumor cells and their supporting BM microenvironment and thereby both suppress tumor cell growth and abrogate MM-induced bone disease.
摘要
因此，我们的研究结果为在多发性骨髓瘤和华氏巨球蛋白血症中研究布鲁顿酪氨酸激酶（Btk）抑制剂提供了有力的理论依据，以靶向肿瘤细胞及其支持性骨髓微环境，从而既抑制肿瘤细胞生长，又消除多发性骨髓瘤引起的骨病。
相似文献
1
Bruton's tyrosine kinase: oncotarget in myeloma.
Oncotarget. 2012 Sep;3(9):913-4. doi: 10.18632/oncotarget.655.
2
BTK inhibition in myeloma: targeting the seed and the soil.
Blood. 2012 Aug 30;120(9):1757-9. doi: 10.1182/blood-2012-07-439216.
3
[Ibrutinib prescription in B-cell lymphoid neoplasms].
Bull Cancer. 2016 Feb;103(2):127-37. doi: 10.1016/j.bulcan.2015.12.003. Epub 2016 Jan 25.
4
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Blood. 2012 Aug 30;120(9):1877-87. doi: 10.1182/blood-2011-12-396853. Epub 2012 Jun 11.
5
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Org Biomol Chem. 2015 May 14;13(18):5147-57. doi: 10.1039/c5ob00474h.
6
Ibrutinib for the treatment of Waldenström macroglobulinemia.
Expert Rev Hematol. 2015 Oct;8(5):569-79. doi: 10.1586/17474086.2015.1061427. Epub 2015 Jul 2.
7
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Am J Hematol. 2013 Jun;88(6):463-71. doi: 10.1002/ajh.23433. Epub 2013 Mar 28.
8
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Future Med Chem. 2018 Feb;10(3):343-356. doi: 10.4155/fmc-2017-0145. Epub 2018 Jan 19.
9
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Hematol Oncol Clin North Am. 2018 Oct;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012. Epub 2018 Jul 19.
10
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Expert Rev Clin Pharmacol. 2021 Nov;14(11):1329-1344. doi: 10.1080/17512433.2021.1978288. Epub 2021 Sep 20.
引用本文的文献
1
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma.
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):173-179. doi: 10.1182/hematology.2022000335.
2
Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives.
Pharmaceutics. 2022 Aug 25;14(9):1784. doi: 10.3390/pharmaceutics14091784.
3
Bruton's Tyrosine Kinase Targeting in Multiple Myeloma.
Int J Mol Sci. 2021 May 27;22(11):5707. doi: 10.3390/ijms22115707.
4
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Br J Haematol. 2018 Mar;180(6):821-830. doi: 10.1111/bjh.15058. Epub 2018 Feb 13.
5
BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling.
Oncotarget. 2017 May 23;8(34):56858-56867. doi: 10.18632/oncotarget.18096. eCollection 2017 Aug 22.
6
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Oncotarget. 2015 Sep 29;6(29):27388-402. doi: 10.18632/oncotarget.4489.
7
Ibrutinib: from bench side to clinical implications.
Med Oncol. 2015 Sep;32(9):225. doi: 10.1007/s12032-015-0669-9. Epub 2015 Jul 30.
8
Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression.
Bioconjug Chem. 2015 Aug 19;26(8):1513-8. doi: 10.1021/acs.bioconjchem.5b00152. Epub 2015 Jun 9.
9
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.
Oncotarget. 2014 Oct 30;5(20):9930-8. doi: 10.18632/oncotarget.2479.
10
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.
Cell Cycle. 2013 Sep 1;12(17):2760-73. doi: 10.4161/cc.25951. Epub 2013 Aug 9.
本文引用的文献
1
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
2
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Cancer Cell. 2012 Jun 12;21(6):723-37. doi: 10.1016/j.ccr.2012.05.024.
3
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Blood. 2012 Aug 30;120(9):1877-87. doi: 10.1182/blood-2011-12-396853. Epub 2012 Jun 11.
4
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.
5
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
Arthritis Res Ther. 2011 Jul 13;13(4):R115. doi: 10.1186/ar3400.
6
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.
Cell. 2008 Mar 7;132(5):794-806. doi: 10.1016/j.cell.2007.12.037.
7
Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
J Immunol. 1994 Jan 15;152(2):557-65.
Zotero 插件